Key Stats for Pfizer Stock
- Current Price: $25.01
- Target Price (Mid): ~$29
- Street Target: ~$29
- Potential Total Return (price): ~14%
- Annualized IRR: ~3% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Pfizer (PFE) reports second-quarter results before the market opens on Tuesday, August 4, and the headline number is almost beside the point. Wall Street expects adjusted earnings per share near $0.68 on revenue around $14.45 billion, a roughly 13% drop on the bottom line as pandemic-era sales keep fading. Pfizer has topped estimates four quarters running, so a beat on that soft figure would surprise no one.
The stock closed July at $25.01, near a 52-week low of $23.40 and about 13% below its high. Two things make this print different from a routine beat: a bladder-cancer approval that landed on July 10, and the fact that this is CFO Dave Denton’s final earnings call before he departs on August 15. How the full-year guide gets framed, and by whom, carries unusual weight.
The Approval That Widened the Oncology Story
On July 10, the FDA approved PADCEV, the Pfizer and Astellas antibody-drug conjugate, in combination with Merck’s Keytruda as treatment for muscle-invasive bladder cancer regardless of cisplatin eligibility. The approval extended a November 2025 clearance from cisplatin-ineligible patients to all eligible patients, based on Phase 3 EV-304 data showing a near 50% reduction in the risk of recurrence, progression, or death. It is the first platinum-free regimen cleared for that setting.
That matters because PADCEV sits inside the Seagen franchise, one of the fastest-growing pieces of Pfizer’s portfolio. Investors will want confirmation on the Q2 call that oncology momentum held. It is the clearest evidence the post-COVID growth engine is real, and it partly offsets the late-June setback when Pfizer’s sigvotatug vedotin missed its overall survival endpoint in second-line lung cancer. Management flagged that risk in advance: at the Goldman Sachs Healthcare Conference on June 8, CEO Albert Bourla noted that “no ADC so far was able to be successful” in that monotherapy setting. The market has absorbed the miss. The question on August 4 is whether the commercial base grew fast enough to make pipeline setbacks survivable.
See historical and forward estimates for Pfizer stock (It’s free!) >>>
The $5 Billion COVID Line Bourla Drew in June
Here is what the market cannot yet price. Pfizer reaffirmed full-year revenue of $59.5 billion to $62.5 billion and adjusted EPS of $2.80 to $3.00 in May, and left it untouched. Bourla admitted at Goldman that he was tempted to raise after a strong first quarter, but never did so in Q1. Q2 removes that excuse, if the numbers cooperate.
The variable that decides it is COVID. Pfizer set 2026 COVID guidance at $5 billion, down from $6.5 billion, specifically to derisk it. Then Bourla named the catch. “The treatment is absolutely correlated with the level of infections,” he said, separating the volatile Paxlovid line from the steadier vaccine. A quiet summer means COVID runs below last year, and management stays cautious. An August or September wave means it runs above, and a raise becomes far easier to justify. That single distinction, treatment versus vaccine, is the swing factor into the print. At roughly 8.8 times forward earnings, well under most large-cap pharma peers, the stock already prices a business in slight decline, so the guide is the cleanest signal of whether that pessimism is warranted.
See how Pfizer performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $25.01
- Target Price (Mid): ~$29
- Potential Total Return (price): ~14%
- Annualized IRR: ~3% / year
See analysts’ growth forecasts and price targets for Pfizer stock (It’s free!) >>>
TIKR’s mid-case values Pfizer near $29, or about 14% of price appreciation above the current level, which works out to an annualized return of around 3% per year on price alone. That is a modest number, and it is honest about what this stock is: an income holding, not a growth story. The roughly 7% dividend yield sits on top of that price return and, for an income-oriented holder, matters as much as the target itself.
The revenue path leans on two drivers: the launched and acquired portfolio compounding off the roughly $12 billion annualized base Bourla cited in June, and the Seagen oncology franchise extending its momentum as approvals like the July PADCEV label widen the market. The margin driver is the AI-enabled cost transformation Bourla described as scaling through late 2026, which has already lifted adjusted operating margin above pre-pandemic levels. The primary risk is the patent cliff, with forward consensus modeling a slight revenue decline as older products lose exclusivity faster than launches replace them. The upside: non-COVID growth and the 2028 obesity entry pull revenue toward the high-single-digit growth Bourla insists begins in 2029. The downside: the pipeline keeps producing misses like the June lung-cancer readout, and the market keeps paying eight times earnings for a shrinking base.
Conclusion
Watch the full-year guidance line on August 4. Reaffirmed at $59.5 to $62.5 billion in revenue and $2.80 to $3.00 in adjusted EPS, it has not moved since May. A raise, particularly on EPS, would signal management believes the oncology engine can outrun both the COVID fade and the patent cliff, and it would give the eight-times multiple room to expand. A flat reaffirmation paired with soft COVID numbers says the caution still holds and the stock stays a yield play. The call is at 10 AM EDT, and with Denton on his way out, how the guide is framed will matter as much as the number.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Pfizer?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Pfizer, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Pfizer alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
